Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Immunological tolerance and tumor rejection in embryo-aggregated chimeric mice – Lessons for tumor immunity

Authors: Alexander Y Wagner, Eric Holle, Lori Holle, Xianzhong Yu, Günter Schwamberger

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Rejection of transplanted tumors by the immune system is a rare event in syngeneic hosts, and is considered to be dependent on the local interaction of defensive immune reactions and tumor tolerance mechanisms. Here, we have enlisted the aid of a unique set of embryo-aggregated lineage chimeric mice derived from C57/BL6 and FVB donors to study the interplay between local and systemic tumor immunity and tolerance in rejection of mouse B16 melanoma cells, syngeneic to the C57/BL6 donor strain.

Methods

Two variants of embryo-aggregated chimeric mice with either variable or no contribution of C57-derived cells to their skin were generated by the fusion of different ratios of morula stage blastomers. Chimeric mice were analyzed for s.c. growth of B16 tumors in comparison to their respective donor strains as well as normal F1 hybrids, and the relative frequencies of cellular components of the immune system by FACS analysis of peripheral blood or lymph node cells.

Results

B16 tumors grew significantly faster in mice with full chimerism in their skin as compared to syngeneic C57 or semi-syngeneic C57 × FVB F1 hosts. In contrast, s.c. tumor growth was either absent or significantly reduced in chimeric mice lacking C57-derived cells in their skin, but tolerant to C57 tissue in other organs. Comparison of the relative frequencies of various immune cells in the periphery via FACS-analysis did not reveal any significant differences between the two types of chimeric mice with respect to their donor strains.

Conclusion

Our data suggest a complex interplay between mechanisms of local peripheral tolerance and innate antitumor mechanisms possibly involving NK cell allorecognition as a basis for the differential growth or rejection of B16 tumors in these unique chimeric mice, which we suggest to constitute a valuable new model system for the study of immune-mediated tumor rejection.
Appendix
Available only for authorised users
Literature
1.
Boon T, Cerottini JC, Eynde Van den B, Bruggen van der P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994, 12: 337-365.CrossRefPubMed
2.
North RJ: The murine antitumor immune response and its therapeutic manipulation. Adv Immunol. 1984, 35: 89-155.CrossRefPubMed
3.
Berendt M, North R: T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med. 1980, 151: 69-80.CrossRefPubMed
4.
Mills CD, North RJ: Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med. 1983, 157: 1448-1460.CrossRefPubMed
5.
Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory T cells and immune tolerance. Cell. 2008, 133: 775-787.CrossRefPubMed
6.
7.
8.
9.
Mintz B, Silvers WK: "Intrinsic" immunological tolerance in allophenic mice. Science. 1967, 158: 1484-1486.CrossRefPubMed
10.
Tarkowski AK: Mouse chimaeras revisited: recollections and reflections. Int J Dev Biol. 1998, 42: 903-908.PubMed
11.
Nagy A, Gertsenstein M, Vintersten K, Behringer R, Eds: Manipulating the Mouse Embryo. 2002, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor Press, Cold Spring Harbor
12.
Gordon J, Wilson VA, Blair NF, Sheridan J, Farley A, Wilson L, Manley NR, Blackburn CC: Functional evidence for a single endodermal origin for the thymic epithelium. Nat Immunol. 2004, 5: 546-553.CrossRefPubMed
13.
Barnes RD: Tumour immunity in tetraparental mouse chimaeras – a review. Eur J Cancer. 1976, 12: 283-290.CrossRefPubMed
14.
Mintz B, Palm J: Gene control of hematopoiesis. I. Erythrocyte mosaicism and permanent immunological tolerance in allophenic mice. J Exp Med. 1969, 129: 1013-1027.CrossRefPubMedPubMedCentral
15.
Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG: Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature. 2005, 435: 590-597.CrossRefPubMed
16.
Snell GD: T cells, T cells recognition structures, and the major histocompatibility complex. Immunol Rev. 1978, 38: 3-69.CrossRefPubMed
17.
Hogquist KA, Baldwin TA, Jameson SC: Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005, 5: 772-782.CrossRefPubMed
18.
19.
Palmer E: Negative selection – clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol. 2003, 3: 383-391.CrossRefPubMed
20.
Gallegos AM, Bevan MJ: Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation. J Exp Med. 2004, 200: 1039-1049.CrossRefPubMedPubMedCentral
21.
Kyewski B, Derbinski J: Self-representation in the thymus: an extended view. Nat Rev Immunol. 2004, 4: 688-698.CrossRefPubMed
22.
23.
Walker LS, Abbas AK: The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol. 2002, 2: 11-19.CrossRefPubMed
24.
Shevach EM: From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity. 2006, 25: 195-201.CrossRefPubMed
25.
Steinman RM, Nussenzweig MC: Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA. 2002, 99: 351-358.CrossRefPubMedPubMedCentral
26.
27.
Savill J, Dransfield I, Gregory C, Haslett C: A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002, 2: 965-975.CrossRefPubMed
28.
29.
Zinkernagel RM, Doherty PC: Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 1974, 248: 701-702.CrossRefPubMed
30.
Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K: Immunobiology of dendritic cells. Annu Rev Immunol. 2000, 18: 767-811.CrossRefPubMed
31.
Heath WR, Carbone FR: Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol. 2001, 1: 126-134.CrossRefPubMed
32.
33.
Heath WR, Kurts C, Miller JF, Carbone FR: Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med. 1998, 187: 1549-1553.CrossRefPubMedPubMedCentral
34.
Wegmann TG, Hellstrom I, Hellstrom KE: Immunological tolerance: "forbidden clones" allowed in tetraparental mice. Proc Natl Acad Sci USA. 1971, 68: 1644-1647.CrossRefPubMedPubMedCentral
35.
36.
Heeger PS: T-cell allorecognition and transplant rejection: a summary and update. Am J Transplant. 2003, 3: 525-533.CrossRefPubMed
37.
Kreutz M, Fritsche J, Andreesen R: Macrophages in tumor biology. The Macrophage. Edited by: Burke B, Lewis CE. 2002, New York, Oxford University Press, 457-489.
38.
Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S: Functions of natural killer cells. Nat Immunol. 2008, 9: 503-510.CrossRefPubMed
39.
Fidler IJ, Schroit AJ: Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim Biophys Acta. 1988, 948: 151-173.PubMed
40.
41.
Raulet DH: Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol. 2006, 18: 145-150.CrossRefPubMed
42.
43.
Clark EA, Holly RD: Activation of natural killer (NK) cells in vivo with H-2 and non-H-2 alloantigens. Immunogenetics. 1981, 12: 221-235.CrossRefPubMed
44.
Moretta L, Ciccone E, Moretta A, Hoglund P, Ohlen C, Karre K: Allorecognition by NK cells: nonself or no self?. Immunol Today. 1992, 13: 300-306.CrossRefPubMed
45.
Bix M, Liao NS, Zijlstra M, Loring J, Jaenisch R, Raulet D: Rejection of class I MHC-deficient haemopoietic cells by irradiated MHC-matched mice. Nature. 1991, 349: 329-331.CrossRefPubMed
46.
Karre K, Ljunggren HG, Piontek G, Kiessling R: Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986, 319 (6055): 675-678.CrossRefPubMed
47.
Nishi Y, Hosokawa T, Aoike A, Han D, Takehara H, Kawai K, Kamahora T: Characterization of effector cells against B16 melanoma in mice inoculated with allogeneic spleen cells. Microbiol Immunol. 1994, 38: 217-223.CrossRefPubMed
48.
Glas R, Waldenstrom M, Hoglund P, Klein G, Karre K, Ljunggren HG: Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft. Cancer Res. 1995, 55: 1911-1916.PubMed
49.
Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002, 295: 2097-2100.CrossRefPubMed
50.
51.
Ljunggren HG, Malmberg KJ: Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol. 2007, 7: 329-339.CrossRefPubMed
52.
Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L: Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol. 2008, 9: 486-494.CrossRefPubMed
53.
Ryan JC, Naper C, Hayashi S, Daws MR: Physiologic functions of activating natural killer (NK) complex-encoded receptors on NK cells. Immunol Rev. 2001, 181: 126-137.CrossRefPubMed
54.
55.
Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH: Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol. 2000, 1: 119-126.CrossRefPubMed
56.
Cerwenka A, Lanier LL: Ligands for natural killer cell receptors: redundancy or specificity. Immunol Rev. 2001, 181: 158-169.CrossRefPubMed
57.
Johansson MH, Bieberich C, Jay G, Karre K, Hoglund P: Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J Exp Med. 1997, 186: 353-364.CrossRefPubMedPubMedCentral
58.
Horwitz DA, Zheng SG, Gray JD: The role of the combination of IL-2 and TGF-{beta} or IL-10 in the generation and function of CD4+ CD25+ and CD8+regulatory T cell subsets. J Leukoc Biol. 2003, 74: 471-478.CrossRefPubMed
59.
Jarnicki AG, Lysaght J, Todryk S, Mills KH: Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006, 177: 896-904.CrossRefPubMed
60.
Ghiringhelli F, Menard C, Martin F, Zitvogel L: The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev. 2006, 214: 229-238.CrossRefPubMed
Metadata
Title
Immunological tolerance and tumor rejection in embryo-aggregated chimeric mice – Lessons for tumor immunity
Authors
Alexander Y Wagner
Eric Holle
Lori Holle
Xianzhong Yu
Günter Schwamberger
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-370

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level

Research article

Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer?

Research article

Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma

Research article

tabAnti-HER2 (erbB-2) oncogene effects of phenolic compounds directly isolated from commercial Extra-Virgin Olive Oil (EVOO)

Research article

The function of BCL9 in Wnt/β-catenin signaling and colorectal cancer cells

Research article

Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits